The KRAS gene is mutated in approximately 20% of NSCLC cases [56–58], and the EGFR gene is defective in approximately 10% of NSCLC patients and in nearly 50% of non-smoker lung cancer cases [59]. This evidence concerns the gene KRAS and lung cancer.